ShangPharma Biologics Head Mitchell Reff On Biologics R&D In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
ShangPharma’s new Chief Biologic Officer Mitchell Reff discusses the company’s expansion into biologics and his views on biologics development in China.
You may also be interested in...
China's Second-largest CRO Seeks Initial Public Offering In The U.S.
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.